No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Healthcare Information Services
Operating through its subsidiaries across Australia, the United States, the United Kingdom, and Asia, MedAdvisor Limited is dedicated to creating and deploying software solutions. A core offering is the MedAdvisor platform, a comprehensive system for medication management and adherence. This platform is engineered to enhance health outcomes by leveraging technology to connect healthcare professionals with their patients, thereby improving medication compliance through targeted health programs. The company also provides THRiV, an intelligent digital solution focused on adherence, and GuildCare, a cloud-hosted platform that supplies various healthcare solutions and pharmaceutical information to individuals, medical practitioners, and other partners. MedAdvisor Limited was established in 2010 and is headquartered in Camberwell, Australia.
www.mymedadvisor.comNo one on the platform currently holds MDR.AX.
No tracked institution reports a position in MDR.AX as of their last filing.
No one on the platform has traded MDR.AX yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | -48.4% | 45.7% | ||||
| Profit Margin % | -95.6% | -33.6% | -73.0% | |||
| Free Cash Flow Margin % | -22.8% | -11.2% | -54.1% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $112M | +1.5% | $0.00 | $0.00–$0.00 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 2 of the last 5 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2025-08-28 | $-0.02 | $-0.10 | -354.5% |
| 2025-02-27 | $-0.00 | $0.00 | +216.0% |
| 2024-08-29 | $-0.01 | $-0.01 | +7.6% |
| 2022-06-30 | $-0.01 | $-0.03 | -224.3% |
| 2021-12-31 | $-0.01 | $-0.02 | -99.3% |
| +5.71% |
| $3M |
| — |
| FRE.AXFirebrick Pharma Limited | $0.03 | +0.00% | $7M | — |
| IME.AXImExHS Limited | $0.33 | +0.00% | $18M | — |
Source: Financial Modeling Prep · peers by sector/industry